Two-fraction HDR Monotherapy for Localized Prostate Cancer

This study tests a two-session high-dose-rate (HDR) brachytherapy approach — a targeted form of internal radiation delivered directly into the prostate — for men with low to intermediate risk prostate cancer. Researchers want to see if just two radiation sessions are as safe and effective as more conventional multi-session approaches. **You may be eligible if...** - You have been diagnosed with prostate adenocarcinoma (prostate cancer) - Your cancer is classified as low to intermediate risk (per NCCN guidelines) - You have not had any prior treatment for prostate cancer - You are 18 or older - You are physically able to undergo the brachytherapy procedure (ECOG/Karnofsky score within acceptable range) - If you have HIV, hepatitis B, or hepatitis C, these must be well-controlled **You may NOT be eligible if...** - You have had any prior prostate cancer treatment or androgen deprivation therapy - You have high-risk or very high-risk prostate cancer - You are not a suitable candidate for brachytherapy as determined by your radiation oncologist Talk to your doctor to see if this trial is right for you.